No Data
Hokuriku Pharmaceutical: First quarter report 2025
Hokuriku Pharmaceutical: 2024 Annual Report
Hokuriku Pharmaceutical: 2024 Annual Report Summary
Beijing Beilu Pharmaceutical (300016.SZ): Iodinated contrast agent injection approved for market in the EU.
Beijing Beilu Pharmaceutical (300016.SZ) issued an announcement, recently, the company received a notice from the Dutch Medicines Agency based on the European Medicines Agency...
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Beijing Beilu Pharmaceutical (300016.SZ): has not been involved in research related to vaccines.
On March 27, Gelonghui reported that Beijing Beilu Pharmaceutical (300016.SZ) stated on the investor interaction platform that the company's Business encompasses two main Sectors: chemical drugs (including Active Pharmaceutical Ingredients) and Traditional Chinese Medicine. Among them, the chemical drug Sector mainly focuses on the research, production, and sales of contrast agents, hypoglycemic products, and so on; the Traditional Chinese Medicine Sector mainly focuses on the production and sales of products related to the central nervous system, clearing heat and detoxification, and tonic herbs. The company's current research and development pipeline primarily concentrates on the fields of contrast agents, endocrinology, digestive systems, and topical formulations, and does not involve research related to vaccines.